Also, patient clinical trials using IL-2 gene-modified autologous tumour cells have shown antitumour responses with antibody production and MHC-restricted cytotoxicity against autologous tumour cells (Bowman et al, 1998). This evidence concerns the gene HLA-C and neoplasm.